Literature DB >> 26153417

TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Vidhyalakshmi Arumugam1, Theresa Bluemn1, Erin Wesley1, Amanda M Schmidt1, Taku Kambayashi1, Subramaniam Malarkannan1, Matthew J Riese2.   

Abstract

DGK-ζ is a negative regulator of TCR signaling that causes degradation of the second messenger DAG, terminating DAG-mediated activation of Ras and PKCθ. Cytotoxic T cells deficient in DGK-ζ demonstrate enhanced effector functions in vitro and antitumor activity in vivo, perhaps because of insensitivity to inhibitory cytokines. We sought to determine whether the enhanced responsiveness of DGK-ζ-deficient T cells renders them insensitive to the inhibitory cytokine TGF-β and to determine how the loss of DGK-ζ facilitates this insensitivity. We identified decreased transcriptional and functional responses to TGF-β in CD8(+) DGK-ζ(-/-) T cells but preserved TGF-β-mediated conversion of naïve DGK-ζ(-/-) CD4(+) T cells to a regulatory T cell phenotype. Decreased CD8(+) T cell responsiveness to TGF-β did not result from impaired canonical TGF-β signal transduction, because similar levels of TGF-β-R and intracellular Smad components were identified in WT and DGK-ζ(-/-) CD8(+) T cells, and TGF-β-mediated activation of Smad2 was unchanged. Instead, an enhanced TCR signal strength was responsible for TGF-β insensitivity, because (i) loss of DGK-ζ conferred resistance to TGF-β-mediated inhibition of Erk phosphorylation, (ii) TGF-β insensitivity could be recapitulated by exogenous addition of the DAG analog PMA, and (iii) TGF-β sensitivity could be observed in DGK-ζ-deficient T cells at limiting dilutions of TCR stimulation. These data indicate that enhanced TCR signal transduction in the absence of DGK-ζ makes T cells relatively insensitive to TGF-β, in a manner independent of Smads, a finding with practical implications in the development of immunotherapies that target TGF-β. © Society for Leukocyte Biology.

Entities:  

Keywords:  Diacylglycerol; Smad2; diacylglycerol kinase ζ

Mesh:

Substances:

Year:  2015        PMID: 26153417      PMCID: PMC4600064          DOI: 10.1189/jlb.2HIMA1214-578R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Authors:  L Zhang; Z Yu; P Muranski; D C Palmer; N P Restifo; S A Rosenberg; R A Morgan
Journal:  Gene Ther       Date:  2012-09-13       Impact factor: 5.250

2.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer.

Authors:  P Wikström; P Stattin; I Franck-Lissbrant; J E Damber; A Bergh
Journal:  Prostate       Date:  1998-09-15       Impact factor: 4.104

Review 4.  TGF-β: guardian of T cell function.

Authors:  Soyoung A Oh; Ming O Li
Journal:  J Immunol       Date:  2013-10-15       Impact factor: 5.422

Review 5.  Role of diacylglycerol kinases in T cell development and function.

Authors:  Sruti Krishna; Xiaoping Zhong
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

6.  Enhanced T cell responses due to diacylglycerol kinase zeta deficiency.

Authors:  Xiao-Ping Zhong; Ehmonie A Hainey; Benjamin A Olenchock; Martha S Jordan; Jonathan S Maltzman; Kim E Nichols; Hao Shen; Gary A Koretzky
Journal:  Nat Immunol       Date:  2003-07-27       Impact factor: 25.606

7.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.

Authors:  A B Kulkarni; C G Huh; D Becker; A Geiser; M Lyght; K C Flanders; A B Roberts; M B Sporn; J M Ward; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

8.  Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.

Authors:  Matthew J Riese; Liang-Chuan S Wang; Edmund K Moon; Rohan P Joshi; Anjana Ranganathan; Carl H June; Gary A Koretzky; Steven M Albelda
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

9.  Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells.

Authors:  Thomas Gruber; Reinhard Hinterleitner; Natascha Hermann-Kleiter; Marlies Meisel; Ingo Kleiter; Chiuhui Mary Wang; Antonella Viola; Christa Pfeifhofer-Obermair; Gottfried Baier
Journal:  J Mol Cell Biol       Date:  2013-05-24       Impact factor: 6.216

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  12 in total

1.  Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

Authors:  Erin M Wesley; Gang Xin; Donna McAllister; Subramaniam Malarkannan; Debra K Newman; Michael B Dwinell; Weiguo Cui; Bryon D Johnson; Matthew J Riese
Journal:  Immunohorizons       Date:  2018-04-01

Review 2.  The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis.

Authors:  Baode Chen; Chenglin Mu; Zhiwei Zhang; Xuelin He; Xia Liu
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

3.  The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function.

Authors:  Debra K Newman; Guoping Fu; Tamara Adams; Weiguo Cui; Vidhyalakshmi Arumugam; Theresa Bluemn; Matthew J Riese
Journal:  Sci Signal       Date:  2016-03-08       Impact factor: 8.192

4.  Negative control of diacylglycerol kinase ζ-mediated inhibition of T cell receptor signaling by nuclear sequestration in mice.

Authors:  Danli Xie; Shimeng Zhang; Pengcheng Chen; Wenhai Deng; Yun Pan; Jinhai Xie; Jinli Wang; Bryce Liao; John W Sleasman; Xiao-Ping Zhong
Journal:  Eur J Immunol       Date:  2020-07-06       Impact factor: 5.532

Review 5.  Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.

Authors:  Matthew J Riese; Edmund K Moon; Bryon D Johnson; Steven M Albelda
Journal:  Front Cell Dev Biol       Date:  2016-10-17

Review 6.  Diacylglycerol Kinases in T Cell Tolerance and Effector Function.

Authors:  Shelley S Chen; Zhiming Hu; Xiao-Ping Zhong
Journal:  Front Cell Dev Biol       Date:  2016-11-10

7.  DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.

Authors:  Elfriede Noessner
Journal:  Front Cell Dev Biol       Date:  2017-03-03

Review 8.  CAR-T cells: the long and winding road to solid tumors.

Authors:  Maria Michela D'Aloia; Ilaria Grazia Zizzari; Benedetto Sacchetti; Luca Pierelli; Maurizio Alimandi
Journal:  Cell Death Dis       Date:  2018-02-15       Impact factor: 8.469

9.  DGK α and ζ Activities Control TH1 and TH17 Cell Differentiation.

Authors:  Jialong Yang; Hong-Xia Wang; Jinhai Xie; Lei Li; Jinli Wang; Edwin C K Wan; Xiao-Ping Zhong
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

Review 10.  Age-Related Dynamics of Lung-Resident Memory CD8+ T Cells in the Age of COVID-19.

Authors:  Nick P Goplen; In Su Cheon; Jie Sun
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.